IP Library Granted Patent US 7,118,888
Granted Patent B2
US 7,118,888 · App. 10/073,065 · Granted Oct 10, 2006

Gene expression vaccine

Assignees: University of South Florida Board of Trustees; Johns Hopkins University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,118,888
App. No.
10/073,065
Granted
Oct 10, 2006
Kind
B2
Abstract

An effective prophylactic mucosal gene expression vaccine (GXV), made up of a cocktail of at least 4 different plasmid DNAs encoding corresponding RSV antigens, coacervated with chitosan to formulate nanospheres. In a murine model of RSV infection, intranasal administration with GXV results in significant induction of RSV-specific antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and IFN-γ production in the lung and splenocytes. A single dose of GXV induces a drastic reduction of viral titers.

Claims (9)

1. An immunogenic composition comprising nanospheres, wherein said nanospheres comprise plasmid DNA coacervated with chitosan, wherein said plasmid DNA encode respiratory syncytial virus (RSV) antigens M2, F, G, M, SH, NS1, NS2, N, and P, and wherein said plasmid DNA are expressed in vivo, thereby producing each of said RSV antigens.

2. A method for raising an immune response in a host against RSV, comprising administering to the host an immunoeffective amount of the immunogenic composition of claim 1 .

3. The method of claim 2 , wherein said administering is oral or intranasal.

4. The method of claim 2 , wherein said administering does not induce airway hyperreactivity.

5. The method of claim 2 , wherein the immunoeffective amount is administered in a single dose.

6. The method of claim 2 , wherein the immunoeffective amount is about 1 mg/kg host weight.

7. A method of making the immunogenic composition of claim 1 , comprising coacervating the plasmid DNA with chitosan to form the nanospheres.

8. The method of claim 7 , further comprising cloning cDNA encoding the RSV antigens in plasmids to form the plasmid DNA.

9. An immunogenic composition comprising nanospheres, wherein said nanospheres comprise plasmid DNA coacervated with chitosan, wherein said plasmid DNA encode respiratory syncytial virus (RSV) antigens M2, F, G, M, SH, NS1, NS2, N, and P, wherein said immunogenic composition is an inhalant, and wherein said plasmid DNA are expressed in vivo, thereby producing each of said RSV antigens.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 7, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044392/0117 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2006
From: BEHERA, ARUNA K.; CHEN, LI-CHEN; PEREZ DE LA CRUZ, CRISTINA
To: UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES; JOHNS HOPKINS UNIVERSITY
Reel/Frame 018129/0570 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2003
From: MOHAPATRA, SHYAM S.; KUMAR, MUKESH; HUANG, SHAU-KU; LEONG, KAM
To: UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES; JOHNS HOPKINS UNIVERSITY
Reel/Frame 013327/0879 →
Continuity (2)
Provisional Application 6032557300 · Sep 28, 2001
Related Publication 20030068333A1 · Apr 10, 2003